Group 1 - The company held its 19th meeting of the third supervisory board on August 13, 2025, with all three supervisors present, and the meeting was deemed legal and effective [3] - The supervisory board approved the company's 2025 semi-annual report and its summary, confirming that the report's preparation and review processes complied with relevant laws and regulations [4] - The supervisory board also approved the special report on the storage and actual use of raised funds for the first half of 2025, stating that the management of raised funds adhered to regulatory requirements [6] Group 2 - The company plans to change its auditing firm to Ernst & Young Huaming, as the previous firm, Lixin, has provided services for ten consecutive years [24][32] - The decision to change the auditing firm was based on the need for new auditing services aligned with the company's business development and future audit requirements [32] - The company has communicated with both the outgoing and incoming auditing firms regarding this change, and both parties have no objections [32] Group 3 - The company reported that as of June 30, 2025, it had raised a total of RMB 555.86 million from its initial public offering, with a net amount of RMB 496.47 million after deducting related expenses [12][13] - By June 30, 2025, the company had used RMB 515.85 million of the raised funds for projects and incurred RMB 59.39 million in issuance costs, with a remaining balance of RMB 3.06 million in the raised funds account [13] - The company has implemented strict management of raised funds, ensuring they are stored in dedicated accounts and used for their intended purposes [14] Group 4 - The company has proposed changes to its registered capital and amendments to its articles of association, which were approved during the board meeting on August 13, 2025 [38][39] - The registered capital increased from RMB 630.58 million to RMB 634.80 million following the completion of the stock incentive plan [38] - The amendments to the articles of association will be finalized based on the approval from the relevant registration authority [39] Group 5 - The company announced the convening of its second extraordinary general meeting of 2025, scheduled for September 1, 2025, to discuss various proposals [41][42] - The meeting will utilize a combination of on-site and online voting methods, allowing shareholders to participate remotely [43] - Shareholders must register for the meeting by August 29, 2025, and can delegate representatives to attend [55]

Core Viewpoint - The company, Hangzhou Aotai Biotechnology Co., Ltd., is utilizing temporarily idle raised funds for cash management to enhance fund efficiency and returns for shareholders while ensuring that it does not affect the progress of investment projects [1][8]. Fundraising Overview - The company raised a total of RMB 1,804,545,000 through its initial public offering, with a net amount of RMB 1,643,266,906.25 after deducting issuance costs [1]. - The funds are stored in a special account approved by the board of directors, and a tripartite supervision agreement has been signed with the sponsor and the commercial bank [1]. Investment Projects - The raised funds are planned to be invested in projects including the construction of a production and R&D center for in vitro diagnostic reagents, with a total investment of RMB 146,059,100 [2][3]. Cash Management Details - The company plans to use up to RMB 480 million of temporarily idle funds for cash management, investing in low-risk, highly liquid products with a maturity of no more than 12 months [5][6]. - The cash management products include but are not limited to agreement deposits, structured deposits, and large certificates of deposit [5]. Approval Process - The board of directors and the supervisory board have approved the cash management plan, which does not require shareholder approval [7][8]. - The company will ensure compliance with relevant regulations and maintain transparency in information disclosure [5][8]. Impact on Operations - The cash management strategy is designed to improve fund efficiency without impacting the company's daily operations or the progress of investment projects [6][8].

Core Viewpoint - The company, Zhejiang Oriental Gene Biotech Co., Ltd., reported a slight increase in revenue for 2024, but a significant loss in net profit, primarily due to a decline in domestic sales and a contrasting increase in international sales [1][2]. Revenue Analysis - The company's total revenue for 2024 was 828 million yuan, a year-on-year increase of 0.95%, while the net profit attributable to shareholders was -529 million yuan, a year-on-year increase in loss of 33.06% [1]. - Domestic revenue was 207 million yuan, a decline of 35.7%, while international revenue reached 605 million yuan, an increase of 23.14% [1][2]. - The overall product sales volume decreased by 16.1% in 2024 [1]. Product Sales Breakdown - Domestic sales were primarily from the infectious disease testing series, which accounted for 39.52% of domestic revenue, but saw a volume decrease of 21.70% [1]. - The COVID-19 testing series generated 55.33% of domestic revenue but experienced a significant volume decline of 75.37% [1]. - Internationally, the drug testing series accounted for 49.67% of revenue, with a slight increase in sales volume [1][2]. Customer Analysis - The top domestic customers included new clients from trade and existing clients in infectious disease testing, with significant fluctuations in sales due to the COVID-19 product line [2]. - Internationally, major clients included large chain pharmacies in the U.S. and new clients in Mexico, contributing to the overall revenue growth [2][3]. Cost and Profit Margin - The company's operating costs for 2024 were 554 million yuan, an increase of 21.26%, with direct materials and manufacturing costs rising by 15.91% and 54.36%, respectively [5]. - The gross profit margins for domestic and international sales were 54.26% and 24.07%, respectively, both showing a decline compared to the previous year [5][6]. Market Dynamics - The decline in domestic sales was attributed to a significant drop in COVID-19 product sales, while international sales benefited from acquisitions and new product launches [3][5]. - The company expanded its market presence in Africa and introduced new online sales models, contributing to the increase in international revenue [3][4].

Core Viewpoint - Shenzhen Pumen Technology Co., Ltd. has successfully acquired the land use rights for a state-owned construction site in Anhui Province for the "In Vitro Diagnostic Reagent Industrialization Project" at a cost of 3.23 million RMB [1][3]. Group 1: Project Overview - The company approved the investment project on June 24, 2024, and signed an investment agreement with the Anhui He County Economic Development Zone Management Committee [2]. - The project involves establishing a wholly-owned subsidiary, Anhui Puhe Biotechnology Co., Ltd., to operate the investment project [2][3]. - The total area of the project site is 21,516.17 square meters (approximately 32.27 acres), with a required investment intensity of at least 2.4 million RMB per acre [3]. Group 2: Land Acquisition Details - On May 21, 2025, Anhui Puhe signed a confirmation letter with the He County Natural Resources and Planning Bureau regarding the acquisition of the land use rights for the designated plot [3][4]. - The acquisition does not constitute a related party transaction or a significant asset restructuring as defined by the relevant regulations [3][4]. Group 3: Impact on the Company - The land will be utilized for the "In Vitro Diagnostic Reagent Industrialization Project," enhancing the company's R&D and manufacturing capabilities in the East China region [4]. - The project is expected to improve product supply capacity, order response speed, and reduce logistics costs, thereby enhancing profitability and promoting sustainable development [4]. Group 4: Funding and Financial Impact - The funding for the land acquisition and project construction will come from self-owned or self-raised funds, which will not affect the normal operations of the company [4]. - The project is not anticipated to have a significant impact on the company's financial or operational status [4].

Core Viewpoint - The company reported a decline in net profit for the first quarter of 2025, primarily due to changes in the VAT calculation method for in vitro diagnostic reagents, leading to a decrease in operating revenue compared to the same period last year [4][5][6]. Financial Data Summary - The first quarter financial report is unaudited [3]. - The company's net profit decreased compared to the same period last year, attributed to the adjustment of the VAT calculation method for in vitro diagnostic reagents, resulting in a decline in operating revenue [4]. - The net cash flow from operating activities decreased by 134.97% compared to the same period last year, mainly due to reduced accounts receivable collections from the subsidiary [4]. Shareholder Information - As of the end of the reporting period, the company held 1,291,428 shares in its repurchase account, accounting for 3.23% of the total share capital [6]. Board Meeting Resolutions - The company held its 11th meeting of the second board on April 28, 2025, where several resolutions were passed, including the approval of the 2024 annual general manager's work report and the 2024 annual board work report [9][11]. - The board also approved the 2024 financial settlement report and the 2024 annual report, which will be submitted for shareholder approval [13][16]. Profit Distribution Plan - The company proposed a cash dividend of 1.00 yuan per 10 shares (including tax), with a total distribution amounting to 3,870,857.20 yuan based on the adjusted total shares [99][100]. - The profit distribution plan is subject to approval at the 2024 annual general meeting [101][103]. Related Transactions - The company plans to use idle funds to purchase financial products from Jiangnan Rural Commercial Bank, with a maximum balance of 50 million yuan and a term not exceeding 12 months [63][64]. - This transaction has been approved by the board and will be submitted for shareholder approval [79][80]. Audit Firm Appointment - The company intends to reappoint Lixin Certified Public Accountants as its auditor for the 2025 fiscal year, pending shareholder approval [86][87]. - Lixin has a strong track record and has provided audit services to numerous listed companies [88][89].

华泰联合证券有限责任公司 关于江苏浩欧博生物医药股份有限公司 保荐机构名称：华泰联合证券有限责任公司 被保荐公司简称：江苏浩欧博 保荐代表人姓名：孙圣虎 联系电话：021-38966920 保荐代表人姓名：董雪松 联系电话：021-38966912 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为江苏浩欧博生物医药股份有限公 司（以下简称"浩欧博"、"公司"或"发行人"）首次公开发行股票的保荐机 构，对浩欧博进行持续督导，并出具本持续督导跟踪报告： 一、保荐机构和保荐代表人发现的问题及整改情况 无。 二、重大风险事项 公司面临的风险因素主要包括： （1）新产品研发和注册风险 体外诊断试剂行业是国内新兴的生物制品行业，随着医疗卫生事业的快速发 展，我国对体外诊断试剂产品的要求不断提高，市场需求也在不断变化。作为技 术密集型行业，不断研发出满足市场需求的新产品是公司在行业竞争中持续保持 领先并不断扩大优势的关键因素。体外诊断试剂产品研发周期一般需要 1 年以 上，研发成功后还必须经 ...

保荐总结报告书 华泰联合证券有限责任公司 关于江苏浩欧博生物医药股份有限公司 首次公开发行股票并在科创板上市 之保荐总结报告书 保荐机构名称 华泰联合证券有限责任公司 保荐机构编号 Z26774000 一、保荐机构及保荐代表人承诺 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 会"）、上海证券交易所对保荐总结报告书相关事项进行的任何质询和调查。 法》的有关规定采取的监管措施。 二、保荐机构基本情况 情况 内容 保荐机构名称 华泰联合证券有限责任公司 深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金 注册地址 小镇 B7 栋 401 主要办公地址 上海市浦东新区东方路 18 号保利广场 E 座 20 楼 法定代表人 江禹 联系人 孙圣虎 联系电话 021-38966920 保荐总结报告书 三、发行人基本情况 情况 内容 发行人名称 江苏浩欧博生物医药股份有限公司 证券代码 688656 注册资本 6305.8328 万元 中国（江苏）自由贸易试验区苏州片区苏州工业园区东堰里路 注册地址 中国（江苏）自由贸易试验区苏州片区苏州工业园区东堰里路 主要办公地址 法定代表 ...

四、担保协议的主要内容 公司目前尚未签订具体担保协议。实际业务发生时，担保金额、担保期限、担保费率等内容，由所涉及 公司、贷款银行等金融机构在以上额度内共同协商确定，相关担保事项以正式签署的担保文件为准。 五、担保的原因及必要性 公司为全资子公司提供担保，有利于提高公司整体融资效率，符合公司整体生产经营的实际需要。各担 保对象生产经营情况稳定，无逾期担保事项，担保风险可控，不存在损害公司及股东利益的情形。 江苏浩欧博生物医药股份有限公司 ■ 在担保实际发生时，可以在预计的对公司全资子公司的担保总额度内，相互调剂使用其预计额度。 三、被担保人基本情况 1、苏州浩欧博生物医药销售有限公司 注：以上披露数据为2024年度数据，报表数据经立信会计师事务所（特殊普通合伙）审计。 截至本公告披露日，除本次预计外，公司及子公司不存在为第三方提供担保的事项，公司对子公司提供 的担保总额为人民币2亿元，占公司最近一期经审计净资产及总资产的比例分别为24.63%、19.36%。 六、董事会意见 公司及其子公司对子公司提供的担保，主要为满足公司及子公司的日常经营和融资需求，符合公司经营 发展需要；该等担保对象均为公司子公司，不会损 ...